$A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial$

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial

Background: Genitourinary (GU) or gastrointestinal (GI) complications and tumor relapse can occur in the long term after radiotherapy for prostate cancer. Objective: To assess the late tolerance and relapse-free survival (RFS) in patients undergoing hypofractionated stereotactic boost therapy after...

Full description

Bibliographic Details
Main Authors:	David Pasquier, Philippe Nickers, Didier Peiffert, Philippe Maingon, Pascal Pommier, Thomas Lacornerie, Emmanuelle Tresch, Maël Barthoulot, Eric Lartigau
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	European Urology Open Science
Subjects:	Intermediate-risk prostate cancer Prostate cancer Stereotactic body radiotherapy Stereotactic body radiotherapy boost
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168323003567

Similar Items

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
by: Seth R. Blacksburg, et al.
Published: (2020-12-01)

Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history
by: Maxime Galienne, et al.
Published: (2024-05-01)

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
by: Luke Nicholls, et al.
Published: (2020-11-01)

Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center
by: Thomas Leroy, et al.
Published: (2017-06-01)

Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer
by: Christoph A. Fink, et al.
Published: (2024-02-01)

Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
by: Kristiina Vuolukka, et al.
Published: (2020-07-01)

Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy
by: Piotr Milecki, et al.
Published: (2023-01-01)

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
by: Takuro Kainuma, et al.
Published: (2019-09-01)

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
by: Yeon Joo Kim, et al.
Published: (2018-04-01)

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
by: Noura Radwan, et al.
Published: (2017-06-01)

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol
by: Maximilien Rogé, et al.
Published: (2023-05-01)

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer
by: Carole Mercier, et al.
Published: (2022-04-01)

Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk
by: Marcin Miszczyk, et al.
Published: (2022-09-01)

Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity
by: Marcin Miszczyk, et al.
Published: (2023-02-01)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High Risk Localized Prostate Cancer
by: Yu-Wei eLin, et al.
Published: (2014-10-01)

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
by: Katz Alan, et al.
Published: (2012-11-01)

Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech
by: Eric Wegener, et al.
Published: (2023-03-01)

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer
by: Francesco Cuccia, et al.
Published: (2021-04-01)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
by: Ju Andrew W, et al.
Published: (2013-01-01)

Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
by: C.A. Fink, et al.
Published: (2024-05-01)

Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15–01)
by: Younghee Park, et al.
Published: (2018-11-01)

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial
by: Valentina Borzillo, et al.
Published: (2023-11-01)

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
by: Kyohei Fujii, et al.
Published: (2023-05-01)

Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity
by: Ragu Ratnakumaran, et al.
Published: (2024-05-01)

Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience
by: Francesco Cuccia, et al.
Published: (2023-08-01)

Current Approaches in Prostate Cancer Radiotherapy
by: Didem Karacetin
Published: (2021-01-01)

Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy
by: Francesco Cuccia, et al.
Published: (2020-07-01)

Stereotactic Body Radiotherapy as Treatment for Organ Confined Low and Intermediate Risk Prostate Carcinoma, a Seven Year Study
by: Alan Jay Katz, et al.
Published: (2014-09-01)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01)

Prostate deformation during hypofractionated radiotherapy: an analysis of implanted fiducial marker displacement
by: Lukas Knybel, et al.
Published: (2021-12-01)

A feasibility study of stereotactic radiosurgery/stereotactic body radiotherapy/stereotactic ablative radiotherapy practice using tomoedge in helical tomotherapy for lung, liver, and spine targets
by: N V. N. Madhusudhana Sresty, et al.
Published: (2021-01-01)

CBCT evaluation of inter- and intra-fraction motions during prostate stereotactic body radiotherapy: a technical note
by: Omar Jmour, et al.
Published: (2020-04-01)

Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy “Moroccan experience”
by: Asmâa Naim, et al.
Published: (2024-02-01)

Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy
by: Harish N. Vasudevan, et al.
Published: (2017-06-01)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
by: Jeong Hoon Phak, et al.
Published: (2016-03-01)

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer
by: Katrina Woodford, et al.
Published: (2017-10-01)

Highlights on the Management of Oligometastatic Disease
by: Salem M. Alshehri, et al.
Published: (2020-02-01)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
by: Hun Jung Kim, et al.
Published: (2015-12-01)

Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety
by: Isaure Roquette, et al.
Published: (2022-08-01)

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
by: David Pasquier, et al.
Published: (2017-01-01)